PIPAC plus chemo for limited peritoneal stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment called PIPAC (medicine delivered into the abdomen through a small scope) along with “multimodal” therapy, including chemotherapy, for stomach cancer that has spread only in the lining of the abdomen in limited amounts. It may help control the cancer and prevent progression after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach cancer that can be removed (resectable) and a confirmed positive peritoneal (abdominal lining) test from laparoscopy
- Your peritoneal cancer spread is low, with PCI 6 or less
- Your general health score is ECOG 0–1 (you’re able to care for yourself and do light work)
- Your cancer spread is only in the abdomen lining (no metastases outside the abdomen)
- You can take the planned medicines, and you have no major allergy to cisplatin or doxorubicin
- Your blood counts, liver and kidney function, and heart health are adequate (and you’re not pregnant or breastfeeding)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special type of chemotherapy sprayed directly into the abdomen (PIPAC) to standard chemotherapy is safer and works better for stomach cancer that has spread only to the lining of the abdomen.
This trial tests a combination of a special chemotherapy sprayed into the abdomen (PIPAC) and a minimally invasive surgery to remove the stomach in people with high-risk stomach cancer. The goal is to see if this approach can improve outcomes for patients whose cancer has grown into the stomach wall or spread to abdominal fluid but not to other organs.
This trial tests if a special type of chemotherapy delivered as a mist during surgery (PIPAC) can help prevent the spread of stomach cancer. It is for people with advanced but not yet metastatic stomach cancer who have not had prior treatment.
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
This trial tests a new way to deliver chemotherapy directly into the abdomen using a spray (called PIPAC) in people with stomach cancer that has spread to the lining of the belly. The aim is to see if it can help control the cancer with fewer side effects.
This study tests a new way to deliver chemotherapy directly into the abdomen (called PIPAC) for women with advanced ovarian cancer who cannot have surgery to remove all tumors. The goal is to see if this approach is safe and helps slow cancer growth.
Hear when a new Oligometastatic Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.